Cognitive Function and Quality of Life in Interferon Therapy for Melanoma
- 1 August 2000
- journal article
- clinical trial
- Published by SAGE Publications in Clinical Nursing Research
- Vol. 9 (3), 352-363
- https://doi.org/10.1177/10547730022158537
Abstract
The purpose of this pilot study was to describe short and long-term changes in cognitive function and quality of life in patients with melanoma receiving interferon (IFN) -2b. This study used a three-group, repeated measures design in which cognitive function and quality of life were evaluated prior to initiation of treatment at 3-month intervals during treatment and 3 months following the completion of treatment. The sample consisted of 16 adults with Stage II or III melanoma, randomized to one of three treatment groups. Participants in Arm A received high-dose IFN -2b, those in Arm B received low-dose IFN• -2b, and those in Arm C received no therapy (control). No significant changes in cognitive function were detected. In participants in ArmA, there was a significant deterioration in the physical well-being dimension of quality of life from baseline to 3 months after beginning therapy.Keywords
This publication has 14 references indexed in Scilit:
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemiaNeurology, 1995
- Reversible cognitive decline during high-dose α-interferon treatmentPharmacology Biochemistry and Behavior, 1994
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993
- Cognitive functioning in cancer patientsNeurology, 1992
- Psychomotor Slowing Is Associated With Distal Symmetrical Polyneuropathy in Adults With Diabetes MellitusDiabetes, 1992
- Persistent neurotoxicity of systemically administered interferon‐alphaNeurology, 1991
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- Central nervous system toxicity of interferonBritish Journal of Cancer, 1983
- Validity of the Trail Making Test as an Indicator of Organic Brain DamagePublished by SAGE Publications ,1958